miR-708-5p enhances erlotinib/paclitaxel efficacy and overcomes chemoresistance in lung cancer cells

Lung cancer is a collection of aggressive tumors generally not diagnosed until late-stage, resulting in high mortality rates. The vast majority of non-small cell lung cancer (NSCLC) patients undergo combinatory chemotherapeutic treatment, which initially reduces tumor growth, but frequently becomes...

Descripción completa

Detalles Bibliográficos
Autores principales: Monteleone, Nicholas J., Lutz, Carol S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7771713/
https://www.ncbi.nlm.nih.gov/pubmed/33473256
http://dx.doi.org/10.18632/oncotarget.27840

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7771713/
https://www.ncbi.nlm.nih.gov/pubmed/33473256
http://dx.doi.org/10.18632/oncotarget.27840

Ejemplares similares